Home › Crohn's Disease › Texas
Crohn's Disease clinical trials in Texas
36 studies for Crohn's Disease are looking for participants at sites in Texas.
Cities in Texas
- Houston17 studies
- Tyler16 studies
- San Antonio15 studies
- Lubbock10 studies
- Lewisville9 studies
- Dallas9 studies
- Round Rock7 studies
- The Woodlands6 studies
- Arlington5 studies
- Fort Worth5 studies
- Austin4 studies
- Garland4 studies
- League City3 studies
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Novel Research - Bellaire /ID# 280925, Bellaire
- GI Alliance -Garland /ID# 284253, Garland
- Amel Med /ID# 283864, Georgetown
- and 7 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07697456A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Baylor University Medical Center ( Site 5031), Dallas
- Epic Medical Research - Mesquite ( Site 5153), Denton
- Baylor College of Medicine Medical Center ( Site 5020), Houston
- and 6 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 29, 2026 · NCT06430801A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- DFW Clinical Trials, Carrollton
- Lubbock Gastroenterology, Lubbock
- Gastroenterology Research of America, LLC, San Antonio
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Novel Research, LLC, Bellaire
- One of a Kind Clinical research Center TX LLC, Kingwood
- Southern Star Research Institute, LLC, San Antonio
- and 1 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06233461A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- The University of Texas at Austin, Austin
- DFW Clinical Trials, Carrollton
- Baylor University Medical Center, Dallas
- and 5 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Cook Childrens Medical Center, Fort Worth
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 25, 2026 · NCT05923073A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Cook Childrens Medical Center, Fort Worth
RecruitingPhase 3
Ages 3 and older · All sexes · Updated Sep 25, 2026 · NCT06663332Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Gi Alliance - Cedar Park /ID# 268153, Cedar Park
- Houston Methodist Hospital /ID# 265533, Houston
- Caprock Gastro Research - Lubbock /ID# 265541, Lubbock
- and 3 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Research of San Antonio, San Antonio
- Southern Star Research Institute, San Antonio
- Tyler Research Institute, Tyler
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Lubbock-Site Number: 8400092, Lubbock
- SMS Clinical Research-Site Number: 8400035, Mesquite
- Gastroenterology Research of San Antonio LLC-Site Number: 8400054, San Antonio
- and 2 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Inquest Clinical Research-Site Number: 8400144, Baytown
- The University of Texas Southwestern Medical Center-Site Number: 8400098, Dallas
- Valley Institute of Research-Site Number: 8400004, Harlingen
- and 8 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- One of a Kind Clinical Research Center - Kingwood, Kingwood
- Southern Star Research Institute, San Antonio
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483099A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- GI Alliance - Cedar Park, Cedar Park
- North Texas Gastroenterology, Denton
- The University of Texas Health Science Center at Houston, Houston
- and 3 more
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 22, 2026 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- One of a Kind Clinical Research Center - Kingwood, Kingwood
- Southern Star Research Institute, San Antonio
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Cook Children's Medical Center, Fort Worth
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- The Clinical Trials Network CTNX LLC, El Paso
- Amel Med LLC, Georgetown
- Kelsey Research Foundation, Houston
- and 7 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT06581328A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Texas Digestive Disease Consultants Cedar Park, Cedar Park
- GI Alliance - Digestive Health Associates of Texas, Dallas
- The University of Texas Health Science Center at Houston, Houston
- and 7 more
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- GI Alliance - Digestive Health Associates of Texas - DHAT ( Site 0290), Garland
- GI Alliance - Lubbock ( Site 0288), Lubbock
- Caprock Gastro Research ( Site 0293), Lubbock
- and 3 more
RecruitingPhase 3
All ages · All sexes · Updated Sep 9, 2026 · NCT06651281Standardized Microbiota Transplant Therapy in Crohn's Disease
- UT Southwestern, Dallas
RecruitingPhase 2
Ages 18 to 89 · All sexes · Updated Sep 8, 2026 · NCT06631586A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- BAMC, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT04372108A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Tyler Research Institute, LLC, Tyler
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Cook Children's Medical Center, Fort Worth
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Texas Southwestern, Dallas
- Baylor College of Medicine, Houston
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173HB-adMSCs for the Treatment of Crohn's Disease
- Hope Biosciences Research Foundation, Sugar Land
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Aug 6, 2026 · NCT07077746A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Southern Star Research Institute, LLC, San Antonio
- Tyler Research Institute, LLC, Tyler
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated May 27, 2026 · NCT06227910A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Tyler Research Institute, LLC, Tyler
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated May 22, 2026 · NCT06764615Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT04751396A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Texas Children's Hospital - Baylor - PIN, Houston
RecruitingPhase 3
Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Texas Children's Hospital, Houston
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Central Texas Clinical Research, LLC, Austin
- Inquest Clinical Research, Baytown
- Novel Research, LLC, Bellaire
- and 8 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400002, Fredericksburg
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Mar 27, 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Dallas
- Mirador Therapeutics Selected Site, Garland
- Mirador Therapeutics Selected Site, Georgetown
- and 5 more
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
- Houston Methodist Hospital, Houston
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Jan 15, 2026 · NCT06257706Beta-Hydroxybutyrate Feasibility Treating IBD
- University of Texas at Austin, Austin
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 19, 2024 · NCT06351124Registry and Biorepository for IBD in Central Texas
- Dell Medical School, UT Austin, Austin
RecruitingObservational study
Ages 18 to 100 · All sexes · Updated May 18, 2021 · NCT04617184From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.